Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
Incylong,
Good points. However, I respectfully disagree. Assay development has become of increasing strategic importance to VRTX and will continue to do so. So much so that it no longer makes sense to license the technology. Good assays are more important than fast assays and ABSC has the goods.

Regarding VRTX's cash. You are right that the ABSC will not affect VRTX's cash burn rate. I follow VRTX closely and do not recall management saying that they have more targets now than they can fund the development of. To the contrary VRTX is looking to expland the pipeline significantly every year. Most important is that they will do so at a much lower cost than traditional drug development. Yes there is risk that VRTX will not bring drugs to market and will run out of cash in the future. This is the general risk of investing in all drug development companies. Is VRTX's risk greater than its peers? No easy answer. You can use clinical index or another metric as a first approximation but ultimately it comes down to a subjective assessment re: their technology and business model.

CV

Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.